Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?

Expert Opinion on Pharmacotherapy
Margherita TortiFabrizio Stocchi

Abstract

Istradefylline (ISD) is a new drug developed for the treatment of Parkinson's disease (PD). It is an adenosine receptor A2A antagonists that will represent an important option for patients with advanced PD where it has been demonstrated efficacy in decreasing daily OFF time and is well tolerated. ISD has been marketed in Japan since May 2013. Areas covered: The objective of this review is to summarize evidences emerged from clinical studies that have demonstrated the efficacy of ISD in advanced parkinsonian patients. It will then focus on the potential role in treating non-motor symptoms (NMS) and cognitive decline, which heavily affect quality of life for PD patients. Its putative role as neuroprotective agent will also be discussed. Expert opinion: ISD might represent an alternative option for patients with advanced PD. The reduction of OFF time highlighted in pivotal trials is comparable to that obtained with different levodopa adjunct therapies. The low profile of side effects makes ISD a more suitable drug for advanced patients whose illness is complicated by depression or cognitive impairment. Future studies are warranted to investigate the possible effects of this drug to delay the occurrence of dyskinesia and to impact ...Continue Reading

References

Mar 21, 2002·Journal of Neurochemistry·Ken IkedaYoshihisa Kuwana
Aug 13, 2003·Neurology·Robert A HauserUNKNOWN Istradefylline US-001 Study Group
Dec 10, 2003·Neurology·Malika El YacoubiJean-Marie Vaugeois
Dec 10, 2003·Neurology·Yoshihiro UradeOsamu Hayaishi
Jul 12, 2005·Expert Opinion on Investigational Drugs·Peter Jenner
Oct 4, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserUNKNOWN Istradefylline 6002-US-013 Study Group
Jul 21, 2009·Parkinsonism & Related Disorders·H H FernandezUNKNOWN 6002-US-051 Study Group
Mar 17, 2010·Neurobiology of Disease·Francesco NapolitanoAntonio Pisani
Mar 27, 2010·Parkinsonism & Related Disorders·Stewart FactorUNKNOWN Istradefylline 6002-US-007 Study Group
Jul 16, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Yoshikuni MizunoUNKNOWN Japanese Istradefylline Study Group
Oct 18, 2011·Parkinsonism & Related Disorders·Emmanuelle PourcherPhilip Chaikin
May 16, 2012·Current Neurology and Neuroscience Reports·Patrick Hickey, Mark Stacy
Mar 14, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Yoshikuni MizunoUNKNOWN Japanese Istradefylline Study Group
Jul 25, 2013·Geriatrics & Gerontology International·Hui Qi, Shixue Li
Sep 2, 2014·International Review of Neurobiology·Peter Jenner
Mar 15, 2015·Clinical Neuropharmacology·Tomoyoshi KondoUNKNOWN Japanese Istradefylline Study Group
Dec 3, 2015·Expert Review of Neurotherapeutics·Ruxandra Julia Vorovenci, Angelo Antonini
Dec 5, 2015·Current Neuropharmacology·Li-Li ZhangXiao-Ping Wang
Jul 9, 2016·International Journal of Urology : Official Journal of the Japanese Urological Association·Takeya KittaNobuo Shinohara
Sep 6, 2017·Journal of the Neurological Sciences·Keisuke SuzukiKoichi Hirata
Dec 23, 2017·Scientific Reports·Wataru SakoRyuji Kaji
Feb 7, 2018·Journal of the Neurological Sciences·Keisuke SuzukiKoichi Hirata

❮ Previous
Next ❯

Citations

Apr 12, 2019·Biomolecules·Fabio Del BelloWilma Quaglia
Jun 25, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·Joseph Jankovic, Eng King Tan
May 26, 2020·CNS & Neurological Disorders Drug Targets·Andrew SchneiderYoussef Sari
Jan 16, 2021·European Journal of Pharmacology·Bhupesh VaidyaShyam Sunder Sharma

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Pharmacotherapy
Fabrizio StocchiMargherita Torti
Movement Disorders : Official Journal of the Movement Disorder Society
Yoshikuni MizunoJapanese Istradefylline Study Group
Journal of the Neurological Sciences
Diego Santos-García, Raúl de la Fuente-Fernández
© 2022 Meta ULC. All rights reserved